

community, corporate, federal, and other stakeholders to develop effective HAI programs that rely upon such these stakeholders for success. State and local public health programs play a central role in these programs because they bridge healthcare and the community. They may regulate and assess facilities, collect and validate data on infections, and implement prevention programs. Myriad other state, federal, and privately supported stakeholders play essential roles. CDC is developing a framework for highly effective state HAI/AR programs that describes core program elements and can be used as a strategic tool, both in day to day processes and in a public health crisis, such the COVID-19 response. Program elements may include engaged leaders and champions, reliable data for action, effective policies, evaluation, program innovation, communications, and partner networks. This presentation describes a success framework for developing and leveraging HAI/AR partner networks to achieve and sustain their capacities and impact.

Methods: CDC collected qualitative data in select states and combined with expert opinion to draft core elements for success among a network of partners working to achieve HAI/AR and COVID-19 response and prevention in states. The core elements serve as a foundation for the framework. Ongoing analyses will inform refinement of the core elements and framework. The CDC is gathering stakeholders' input on the framework for applicability and usability in states, with the goal of national implementation. **Results:** Currently, data indicate the following core elements for partner networks: leadership, strategy and structure; policies; innovation and adaptability; implementation; expertise and resources; communications; and monitoring and evaluation. The framework includes a process for partner network development and sustenance, maturity levels, and supporting tools. States have reported support for core elements and agreed that a success framework is beneficial to achieving core elements. Multiple states have reported support for a process that includes building partner networks and clearly defining roles, as a critical step toward full implementation of Program core elements. **Conclusions:** A framework for building high-level strategy and competency in partner networks has never been developed for HAI/AR programs. Effective partner networks represent an essential core element of a comprehensive state HAI/AR program. This framework could be applied to a variety of programs and public health contexts, increasing the effectiveness of partner networks.

Funding: None

Disclosures: None

Doi:10.1017/ice.2020.716

Presentation Type:

Poster Presentation


Creating an Outpatient-Specific Antibiogram to Guide Treatment for Urinary Tract Infections

Larissa Grigoryan, Baylor College of Medicine; Melanie Goebel, Baylor College of Medicine; Samuel Willis, Baylor College of Medicine; Lisa Danek, Baylor College of Medicine; Jennifer Matas, Baylor College of Medicine; Neal Kachalia, Harris Health System; Anna Katta, Harris Health System; Kenneth Muldrew, Baylor College of Medicine; Mohammad Zare, University of Texas McGovern Medical School; Forrest Hudson, Harris Health System; Robert Atmar, Baylor College of Medicine; Barbara Trautner, Baylor College of Medicine

Background: Outpatients with uncomplicated urinary tract infections (UTIs) are often treated empirically without culture, whereas urine cultures are typically collected from patients with complicated

UTI. Susceptibilities for fosfomycin (a first-line agent) are not routinely performed or reported in the antibiogram. Understanding the prevalence of antibiotic resistance for UTI is critical for empiric treatment and antibiotic stewardship in primary care. **Methods:** We developed a UTI-focused antibiogram from a prospective sample of outpatients (women and men) with UTIs from 2 public family medicine clinics in an urban area with a diverse, international population (November 2018 to present). During the study period, providers ordered a urine culture for any adult patient presenting with UTI symptoms, including uncomplicated and complicated infections. We estimated the prevalence of resistance to UTI-relevant antibiotics in the overall study population and compared it between patients born in the United States and other countries. **Results:** We collected 678 urine cultures from 644 unique patients (79% female). Of these cultures, 158 (23.3%) had no growth, 330 (48.7%) grew mixed urogenital flora, and 190 (28.0%) were positive (>10,000 CFU/mL). Patients with positive cultures were mostly female (88.2%), and their mean age was 46.6 ± 14.8 years. Among patients with positive cultures, 42.7% were born in the United States and 57.3% were born Mexico or Central America. *Escherichia coli* was the most commonly isolated organism (Fig. 1). Susceptibility results for *E. coli* and all gram-negative organisms combined are presented in Fig. 2. Susceptibility of uropathogens to TMP-SMX was significantly higher in patients born in the United States compared to patients from Mexico or Central America (82% vs 61%; $P =$

Figure 1. Gram negative isolates from urine cultures (n=103).



*Other category included 1 *Stenotrophomonas* sp., 1 *Providencia* sp., 1 *Acinetobacter* sp., and 1 *Pseudomonas aeruginosa*.

Fig. 1.

Figure 2. Susceptibility pattern for all Gram-negative isolates.




Fig. 2.

.03). Susceptibility to ciprofloxacin was similar in patients born in the United States and other countries (79% vs 72%; $P = .50$). Of 77 *E. coli* isolates, 11 (14%) were positive for extended-spectrum β -lactamase production, including 8 isolates from patients whose country of origin was Mexico or a Central American country. **Conclusions:** More than 20% of outpatients presenting with UTI symptoms had a negative urine culture. Among outpatients with uncomplicated and complicated UTI, uropathogens had a high prevalence of resistance to ciprofloxacin and TMP-SMX, but susceptibility to fosfomycin (restricted in our system) was 100%. Resistance rates for TMP-SMX were higher in patients from Mexico and Central America. Our findings question whether TMP-SMX should remain a first-line agent in US primary-care settings.

Funding: This project was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681.

Disclosures: None

Doi:10.1017/ice.2020.717

Presentation Type:

Poster Presentation

Current Status of Antimicrobial Stewardship Programs in São Paulo Hospitals

Silvia Sato, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil; Geraldine Madalosso, Division of Hospital Infection, Epidemiological Surveillance Center, São Paulo State Health Department; Denise Assis, Division of Nosocomial Infections, Center for Epidemiologic Surveillance ‘Prof. Alexandre Vranjac’, Center of Disease Control, SP; Lauro Perdigão-Neto, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil; Anna Levin, Hospital das Clínicas, University of São Paulo, São Paulo, Brazil; Maura Oliveira, Hospital das Clínicas FMUSP and Hospital Sírio Libanês

Background: Antimicrobial stewardship programs (ASPs) consist of coordinated interventions designed to improve and measure appropriate antimicrobial use. Understanding the current structure of ASPs hospitals will support interventions for improvement or implementation of these programs. **Objective:** We aimed to describe the current status of ASP in hospitals in the state of São Paulo, Brazil. **Methods:** We conducted a cross-sectional survey regarding ASP of hospitals in São Paulo state, Brazil, from March to July 2018. Through interviews by telephone or e-mail, we asked participants which components of IDSA/SHEA and CDC guidelines had been implemented. **Results:** The response rate was 30% (28 of 93 hospitals) and 26 of the hospitals (85%) reported having a formal ASP. Policies, practices, and strategies of surveyed ASP are detailed in Table 1. The most frequently implemented strategies were (1) antimicrobial surgical prophylaxis guideline (100%), (2) empiric sepsis guideline (93%), and (3) presence of ASP team member during bedside rounds (96%). The least commonly implemented strategies included prior authorization for all antimicrobials (11%), pharmacokinetic monitoring and adjustment program for patients on IV aminoglycosides (3%). Regarding metrics of the ASP, the most common indicator was the rates of antimicrobial resistance (77%). Overall, 18 hospitals (19%) used defined daily dose and only 29% used days of therapy. Moreover, 61% of hospitals reported their results to hospital the administration and 39% of hospitals reported their results to the prescribers. **Conclusions:** Most hospitals have a formal ASP, but there are opportunities for improvement. Future efforts should prioritize tracking and reporting ASP metrics.

Strategy	N (%)
Tools to improve antimicrobial prescribing	
Antimicrobial surgical prophylaxis guideline	28 (100)
Empiric sepsis guideline	24 (86)
ID physician available for contact	27 (96)
Presence of ASP team member during bedside rounds	26 (93)
Post prescription auditing	25 (89)
Policy requiring prescribers to document indication for all antibiotics	24 (86)
Provider feedback on prescribing	22 (84)
Prescriber education with formal classes	21 (75)
Systematic evaluation of situations in which antimicrobial spectrum may be redundant	20 (71)
Use of a computerized clinical decision support system for antimicrobial prescription	12 (43)
Prior authorization for selected antimicrobials	13 (46)
Promoting the use of and transition toward oral antimicrobials over IV antimicrobials	13 (46)
Prior authorization for all antimicrobials	3 (11)
Available aminoglycosides serum testing level	5 (18)
Pharmacokinetic monitoring and adjustment program for patients on IV aminoglycosides	1 (3)
Available vancomycin serum testing level	17 (61)
Pharmacokinetic monitoring and adjustment program for patients on IV Vancomycin	18 (67)
Guideline for dose adjustment for renal dysfunction	21 (75)
Guideline for dose adjustment for liver dysfunction	11 (39)
Use of continuous infusion for beta-lactams	19 (68)
Microbiology and laboratory support	
Automated systems for identification of microorganisms	21 (75)
<i>Clostridium difficile</i> tests	23 (82)
Molecular diagnosis for respiratory viruses	17 (61)
Protein C reactive	26 (93)
Procalcitonin	4 (14)
Beta-d-Glucan test	4 (14)
Galactomannan assay	12 (43)
Tracking and Reporting Antibiotic Use and Outcomes	
Rates of antimicrobial resistance profile	22 (77)
Rates of multiresistant bacteria infections	19 (68)
Antimicrobial consumption (Defined Daily Dose)	18 (64)
Adherence to recommendations	12 (43)
Purchasing data	10 (36)
Days of therapy	8 (29)
Rates of <i>Clostridium difficile</i> infection	4 (14)
Reports of indicators to Hospital administration	17 (61)
Reports of indicators to prescribers	11 (39)

Fig. 1.

Funding: None

Disclosures: None

Doi:10.1017/ice.2020.718

Presentation Type:

Poster Presentation

De-escalation of Antibiotics in Severe Sepsis and Septic Shock at a Large Municipal Hospital

Maiko Kondo, NewYork-Presbyterian Weill Cornell Medical Center; Amit Uppal, Department of Medicine, Bellevue Hospital Center; Harold Horowitz, Division of Infectious Diseases, Department of Medicine, New York-Presbyterian Brooklyn Methodist Hospital

Background: Early de-escalation of antibiotics in sepsis may be safe and effective. In our study, we performed a retrospective chart review of patients admitted to a large municipal hospital who were treated for severe sepsis or septic shock to compare outcomes in patients who experienced early de-escalation (DEG) with outcomes of those who did not (NDG).

Methods: The observational study was conducted at Bellevue Hospital Center (an 850-bed municipal hospital affiliated with New York University School of Medicine, New York, NY). Patients admitted from January 1 to December 31, 2015, who were treated for severe sepsis or septic shock during any time of their hospital stay were reviewed for the study. De-escalation was defined as